Dr. Francis J. Giles is the Director of the Northwestern Medicine Developmental Therapeutics Institute and a Professor of Medicine in the Division of Hematology/Oncology within the Feinberg School of Medicine.
Among his many accolades, Dr. Giles was recently elected as a Fellow of the European Academy of Cancer Sciences. He earned his primary medical degree from the National University of Ireland, Galway (NUIG) and a Doctorate in medicine from NUIG in 2003. He is a Fellow of both the Royal College of Physicians of Ireland and the Royal College of Pathology (United Kingdom). Dr. Giles has particular interests in the mentoring of developmental therapeutics physician-scientists and in international collaborations across the bioscience spectrum.
Dr. Giles has held positions including Director of the HRB Clinical Research Facility, Galway. He is a Professor of Cancer Therapeutics at both NUIG and Trinity College Dublin. Previously, Dr. Giles served as Deputy Director of the Cancer Therapy and Research Center at the University of Texas (UT) Health Science Center, San Antonio; Chief of the Division of Hematology and Medical Oncology; and Director of the Institute for Drug Developement. His prior positions include serving as Professor in the Division of Cancer Medicine at the UT MD Anderson Cancer Center, Houston, and as a faculty member at the University of California, Los Angeles, and the University of North Carolina at Chapel Hill. He is the founder and Chairman of both the International Oncology Study Group and the Developmental Therapeutics Consortium. He has authored more than 500 peer-reviewed articles on bioscience research in academic journals.
"The last decade has seen enormous progress in anti-cancer therapy," says Dr. Giles. "We are turning incremental knowledge of the pathologies that drive cancer into very targeted, effective therapies. The Northwestern Medicine Developmental Therapeutics Institute will accelerate this continuum for patients suffering from cancer as well as for patients suffering from the increasing number of non-malignant diseases that share common therapeutic targets with cancer."